My primary research interest involves healthcare outcome analysis using registry and administrative databases such as SEER/SEER-Medicare.
I am interested in advancing the methodology for evaluation of treatment interventions in hematology and oncology using the vast amount of information in such databases, while overcoming the inherent bias of such analyses related to their retrospective nature and limited clinical validation.

Biography

I received my MD diploma from the Medical University of Warsaw in 1999 and completed my postgraduate training at St. Luke's-Roosevelt Hospital Center in New York.
I joined Memorial Hospital of Rhode Island Cancer Center in 2010, where I work as a clinical hematologist/oncologist and teacher.
My research interests involve clinical trials developed in the framework of the Brown University Oncology Group (BrUOG), as well as healthcare outcome research using registry and administrative databases such as SEER/SEER-Medicare.
I am particularly interested in advancing the methodology for evaluation of treatment interventions in hematologic oncology using the vast amount of information in such databases, while overcoming the inherent bias of such analyses related to their retrospective nature and limited clinical validation.

Affiliations

• American Society of Clinical Oncology


• American Society of Hematology

Teaching Experience

Problem-based Learning

View My Full Publication List in pdf format

Selected Publications

• Olszewski AJ, Migdady Y, Boolbol S, Klein P, Boachie-Adjei K, Sakr B, et al. Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. Breast Cancer Research and Treatment. 2013:1-9. doi: 10.1007/s10549-013-2423-3(2013)
• Olszewski AJ, Castillo JJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. Annals of Oncology 2013.doi: 10.1093/annonc/mds644(2013)
• Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Jul 30. doi: 10.1002/cncr.28264.(2013)
• Olszewski AJ. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. Am J Hematol. 2012 Jul 23. doi: 10.1002/ajh.23314.(2012)
• Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: Analysis of the Surveillance, Epidemiology, and End Results database. Cancer 2013 Feb 1;119(3):629-38 doi: 10.1002/cncr.27773.(2012)
• Migdady Y, Olszewski AJ. Evaluation of incidental neutropenia in a multi-ethnic setting. Int J Lab Hematol 2013, 35: e6–e8. DOI: 10.1111/ijlh.12016.(2012)
• Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS. Phase I Study of Oxaliplatin in Combination with Gemcitabine, Irinotecan, and 5-Fluorouracil/Leucovorin (G-FLIE) in Patients with Metastatic Solid Tumors Including Adenocarcinoma of the Pancreas. J Gastrointest Cancer. 2012 Dec 4. doi: 10.1007/s12029-012-9466-2(2012)
• Gavini A, Telang GH, Olszewski AJ. Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. Int J Hematol 2012 Mar;95(3):311-4. DOI: 10.1007/s12185-012-1012-2(2011)
• Olszewski AJ, Grossbard ML, Kozuch P. The Horizon of Antiangiogenic Therapy for Colorectal Cancer. Oncology (Williston Park): March 2005:19(3): 297.(2005)
• Olszewski AJ, Grossbard ML. Empowering targeted therapy: lessons from rituximab. Science STKE. 2004 Jul 6;2004(241):PE30.(2004)
• Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, Friedlander RM. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000 Apr 14;288(5464):335-9. DOI: 10.1126/science.288.5464.335(2000)